Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Company Deals

InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib

Fineline Cube Apr 22, 2026
Company Deals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

Fineline Cube Apr 22, 2026
Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Fineline Cube Apr 21, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China’s CDE Releases 106th Batch of Chemical Generic Reference Preparations with 27 New Specifications and Updated Guidelines

Fineline Cube Apr 23, 2026
Company Drug

FDA Extends Review Timeline for Sanofi’s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026

Fineline Cube Apr 23, 2026
Company Deals

HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies

Fineline Cube Aug 29, 2023

Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech,...

Company Medical Device

Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial

Fineline Cube Aug 29, 2023

Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...

Company Drug

Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...

Company Deals

Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine

Fineline Cube Aug 29, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...

Company Deals

BMS Partners with Cellares for Automated CAR-T Cell Therapy Production

Fineline Cube Aug 29, 2023

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...

Company Deals

Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification

Fineline Cube Aug 29, 2023

A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...

Company

Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales

Fineline Cube Aug 29, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...

Company Drug

Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment

Fineline Cube Aug 29, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...

Company Drug

Zhejiang Huahai Pharmaceutical Receives FDA Approval for Generic Vyvanse

Fineline Cube Aug 29, 2023

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt...

Company

Antengene’s Xpovio Price Reduced by 37% in China, Aiding Patient Access

Fineline Cube Aug 29, 2023

Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio...

Policy / Regulatory

China’s 9th National VBP Tender Round Targets CNS Drugs and Includes Oncology Therapies

Fineline Cube Aug 29, 2023

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Revises Drug Conditional Approval Procedures: Streamlined Processes and Requirements

Fineline Cube Aug 29, 2023

The National Medical Products Administration (NMPA) has released the “Drug Conditional Approval Filing Review and...

Company Deals

GenFleet Therapeutics and Verastem Oncology Ink Licensing Deal for RAS Pathway Cancer Therapies

Fineline Cube Aug 29, 2023

China-based GenFleet Therapeutics has entered into an exclusive licensing and early development agreement with US...

Company Drug

Boehringer Ingelheim Submits Three INDs for Survodutide Phase III Trials in China

Fineline Cube Aug 29, 2023

Germany-based Boehringer Ingelheim (BI) has announced the submission of three Investigational New Drug (IND) filings...

Company

Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half...

Company Medical Device

Allurion’s Non-Invasive Weight-Loss Balloon Debuts at Ruijin Hospital’s Hainan Subsidiary

Fineline Cube Aug 28, 2023

US-based Allurion’s (NYSE: ALUR) weight-loss intragastric balloon has been first applied in Shanghai Ruijin Hospital’s...

Company Drug

Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment

Fineline Cube Aug 28, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...

Company Policy / Regulatory

AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare

Fineline Cube Aug 28, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...

Company Drug

MSD Initiates Phase III Trial for PCSK9 Inhibitor MK-0616 in LDL Cholesterol Reduction

Fineline Cube Aug 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has commenced Phase III development for its experimental...

Company Deals

Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor

Fineline Cube Aug 28, 2023

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement...

Posts pagination

1 … 471 472 473 … 655

Recent updates

  • China’s CDE Releases 106th Batch of Chemical Generic Reference Preparations with 27 New Specifications and Updated Guidelines
  • FDA Extends Review Timeline for Sanofi’s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026
  • NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations
  • Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment
  • Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China’s CDE Releases 106th Batch of Chemical Generic Reference Preparations with 27 New Specifications and Updated Guidelines

Company Drug

FDA Extends Review Timeline for Sanofi’s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026

Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.